<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959228</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0957</org_study_id>
    <nct_id>NCT03959228</nct_id>
  </id_info>
  <brief_title>Impact of Low Protein Diet Supplemented With Ketoanalogues Supplementation on Uremic Toxins Production</brief_title>
  <acronym>KETO-GUT</acronym>
  <official_title>Impact of Low Protein Diet Supplemented With Ketoanalogues on Uremic Toxins Production and Glucose Metabolism in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is associated with accumulation of uremic toxins like p-cresyl&#xD;
      sulfate and indoxyl sulfate that are associated of cardiovascular complication and&#xD;
      perturbation of glucose metabolism. These toxins are produced by fermentation of protein by&#xD;
      intestinal microbiota but the role of low protein diet and ketoanalogue supplementation on&#xD;
      uremic toxins production and microbiota composition are unknown. Low protein diet&#xD;
      supplemented with ketoanalogues is recommended inCKD patients to prevent progression of renal&#xD;
      disease. The aim of this study is to determine the impact of uremic toxins concentration,&#xD;
      microbiota composition and gut hormone involved in carbohydrate metabolism ( GLP-1, FGF19,&#xD;
      bile acids) with low protein diet supplemented with ketoanalogues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Anticipated">December 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indoxyl Sulfate Plasmatic concentration</measure>
    <time_frame>After 3 months of diet</time_frame>
    <description>Concentration mesure of Indoxyl Sulfate Plasmatic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TMAO uremic toxin concentraction ( TMAO, PCS) in plasma</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration mesure of uremic toxin in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMAO uremic toxin concentraction in urine ( IS, PCS)</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration mesure of uremic toxin in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of intestinal microbiota</measure>
    <time_frame>Before three months</time_frame>
    <description>sequencing 16s stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of intestinal microbiota</measure>
    <time_frame>After three months</time_frame>
    <description>sequencing 16s stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion of gut hormone like GLP-1 and FGF19</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of bile acid</measure>
    <time_frame>After 3 months</time_frame>
    <description>composition of bile acid mesure by chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bile acid</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration of bile acid mesure by Chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of endotoxinemia (LPS)</measure>
    <time_frame>After 3 months</time_frame>
    <description>LPS concentration mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>After 3 months</time_frame>
    <description>Nutrional status will be determined with body weight, body composition with bioimpedecemetry, albumin, prealbumin, muscle status with hand grip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcemia</measure>
    <time_frame>After 3 months</time_frame>
    <description>calcemia mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of diet</measure>
    <time_frame>After 3 months</time_frame>
    <description>counting of returned ketosteril tablets</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>referencial diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0.8 g/kg/day of protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>protein very poor diet with additional keto-analogs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>keto-analogs</intervention_name>
    <description>The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).</description>
    <arm_group_label>protein very poor diet with additional keto-analogs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CKD stage 4-5 with estimated glomerular filtration rate &lt; 30 ml/min/1,73m2&#xD;
&#xD;
          -  No dialysis&#xD;
&#xD;
          -  No history of kidney transplantation&#xD;
&#xD;
          -  Non-diabetic (fasting glucose &lt;1.26 g / L, or no insulin or oral antidiabetic therapy)&#xD;
&#xD;
          -  BMI between 18 and 30 kg / m2&#xD;
&#xD;
          -  Patient followed in the nephrology department of Professor FOUQUE at the Lyon Sud&#xD;
             hospital&#xD;
&#xD;
          -  For women of childbearing age, at least one method of contraception recognized as&#xD;
             effective&#xD;
&#xD;
          -  Patient who gave consent to open participation and signed the consent to participate&#xD;
             in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with progressive inflammatory, infectious, cardiovascular or neoplastic&#xD;
             disease&#xD;
&#xD;
          -  Patient refusing a dietary follow-up&#xD;
&#xD;
          -  Patient having a planned transplant or dialysis project in the next 6 months.&#xD;
&#xD;
          -  Patient having a colectomy, resection of the small intestine or cholecystectomy&#xD;
&#xD;
          -  Patient who has received antibiotics, prebiotics, probiotics in the last 3 months.&#xD;
&#xD;
          -  Patient treated with more than 2 g of calcium per day&#xD;
&#xD;
          -  Patient using laxatives (more than 2 per day)&#xD;
&#xD;
          -  Patient having:&#xD;
&#xD;
          -  Uncontrolled metabolic acidosis (bicarbonatemia &lt;18 mM)&#xD;
&#xD;
          -  Hyperparathyroidism (PTH greater than 5 times the upper limit of normal)&#xD;
&#xD;
          -  Hypercalcemia (Calcium&gt; 2.55 mmol / L) or hypophosphoremia &lt;0.70 mmol / L&#xD;
&#xD;
          -  Anemia (hemoglobinemia &lt;80g / L)&#xD;
&#xD;
          -  Undernutrition criteria: albumin &lt;38 g / L or prealbumin &lt;0.3 g / L&#xD;
&#xD;
          -  Known hypersensitivity to any of the substances or excipients of Ketosteril&#xD;
&#xD;
          -  Subject in exclusion period of a previous study&#xD;
&#xD;
          -  Patient not affiliated to social security&#xD;
&#xD;
          -  Patient under guardianship or in the interests of justice&#xD;
&#xD;
          -  Patient who is pregnant, breastfeeding or likely to become pregnant during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laetitia KOPPE, MD</last_name>
    <phone>+33 4 72 67 87 15</phone>
    <phone_ext>+33</phone_ext>
    <email>Laetitia.koppe@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon SUD</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia KOPPE, PhD</last_name>
      <phone>04 72 67 87 15</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.koppe@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Denis FOUQUE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

